TriSalus Life Sciences announced the appointment of David B. Patience as its new Chief Financial Officer, effective July 1, 2025. Mr. Patience will succeed James Young, who stepped down from the role for personal reasons effective May 30, 2025.
During the transition period, Dan Giordano, the company's Vice President of Finance, will serve as acting Chief Financial Officer. Mr. Patience brings extensive experience in capital markets and a proven track record of financial leadership and operational execution, having previously served as CFO at Accelerate Diagnostics.
The company's President and CEO, Mary Szela, stated that Mr. Patience's expertise will be invaluable as TriSalus drives its next phase of growth. This leadership change aims to support the company's strategic financial and operational objectives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.